重组人尿激酶原治疗ST段抬高型心肌梗死的临床疗效分析  

Clinical effect of recombinant human prourokinase on patients with STEMI and its influence on blood flow classification and cardiac function

作　　者：高亚平 高振 GAO Yaping;GAO Zhen(Department of Emergency,Shanxian Central Hospital,Heze,Shandong,274300,China)

机构地区：[1]单县中心医院急诊科,山东菏泽274300

出　　处：《中国冶金工业医学杂志》2024年第6期631-632,共2页Chinese Medical Journal of Metallurgical industry

摘　　要：目的探讨重组人尿激酶原(rhPro-UK)治疗ST段抬高型心肌梗死(STEMI)的临床疗效。方法将2020年9月—2022年4月本院收治的60例STEMI患者以信封法随机分为观察组和对照组,每组各30例。两组均接受经皮冠状动脉介入术(PCI)治疗,对照组给予替罗非班治疗,观察组给予rhPro-UK联合替罗非班治疗。比较两组的TIMI血流分级、心功能指标、心肌损伤标志物指标、主要不良心血管事件(MACE)和不良反应发生率。结果两组治疗后的TIMI分级、各心功能指标、各心肌损伤标志物指标均优于对照组,组间比较差异显著(t=2.915、3.170、3.352、4.803、9.160、6.387,均P<0.05);观察组随访期间的MACE发生率低于对照组,组间比较差异显著(χ^(2)=5.192,P<0.05);两组不良反应发生率比较无显著差异(χ^(2)=0.351,P>0.05)。结论rhPro-UK在STEMI患者PCI治疗中的应用价值显著,可改善TIMI血流分级,提升心功能,减轻心肌损伤程度,降低远期MACE风险。Objective To investigate the clinical efficacy of recombinant human prourokinase(rh Pro-UK)in the treatment of ST-segment elevation myocardial infarction(STEMI).Methods A total of 60 STEMI patients treated in our hospital from September 2020 to April 2022 were randomly divided into an observation group and a control group,with 30 cases in each group.Both groups received percutaneous coronary intervention(PCI),with the control group receiving tirofiban treatment and the observation group receiving rhPro-UK combined with tirofiban.The TIMI blood flow grade,cardiac function indicators,myocardial injury markers,incidence of major adverse cardiovascular events(MACE),and adverse reactions were compared between the two groups.Results After treatment,the TIMI grade,cardiac function indicators,and myocardial injury markers were significantly better in the observation group compared to the control group,with statistically significant differences between the groups(t=2.915,3.170,3.352,4.803,9.160,6.387,all P<0.05).The incidence of MACE during follow-up was lower in the observation group than in the control group,with a statistically significant difference(χ^(2)=5.192,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(χ^(2)=0.351,P>0.05).Conclusion The application of rhPro-UK in PCI treatment for STEMI patients has significant clinical value,as it can improve TIMI blood flow grade,enhance cardiac function,reduce the extent of myocardial injury,and lower the risk of long-term MACE.

关 键 词：心肌梗死 介入治疗 重组人尿激酶原 替罗非班 心功能 

分 类 号：R542.22[医药卫生—心血管疾病]